Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a buy rating in a report issued on Thursday morning. Zacks Investment Research currently has $3.50 price objective on the stock.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
A number of other equities analysts have also recently issued reports on the stock. BidaskClub cut shares of NantHealth from a sell rating to a strong sell rating in a report on Wednesday, December 6th. Canaccord Genuity cut their target price on shares of NantHealth from $6.00 to $5.00 and set a buy rating on the stock in a report on Friday, November 17th. Finally, Jefferies Group reissued a buy rating and issued a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $7.90.
NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. The business had revenue of $21.76 million during the quarter, compared to the consensus estimate of $29.42 million. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.18) earnings per share. analysts anticipate that NantHealth will post -1.35 EPS for the current fiscal year.
In other NantHealth news, COO Ronald Allen Louks sold 26,820 shares of the firm’s stock in a transaction dated Friday, October 6th. The shares were sold at an average price of $4.28, for a total value of $114,789.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 38,770 shares of company stock worth $153,412 in the last three months. 58.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its holdings in shares of NantHealth by 154.7% during the third quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock valued at $299,000 after buying an additional 44,100 shares during the last quarter. Highbridge Capital Management LLC raised its holdings in shares of NantHealth by 6.5% during the third quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock valued at $1,030,000 after buying an additional 15,264 shares during the last quarter. National Planning Corp raised its holdings in shares of NantHealth by 21.1% during the third quarter. National Planning Corp now owns 138,700 shares of the company’s stock valued at $656,000 after buying an additional 24,200 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of NantHealth during the third quarter valued at approximately $365,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of NantHealth during the third quarter valued at approximately $180,000. 7.10% of the stock is currently owned by institutional investors.
WARNING: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/24/nanthealth-nh-raised-to-buy-at-zacks-investment-research.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.